期刊文献+

卵巢上皮性癌的易患风险因素及预防 被引量:9

Risk factors and prevention of ovarian cancer susceptibility
原文传递
导出
摘要 卵巢上皮性癌(epithelial ovarian cancer,EOC)居女性生殖系统恶性肿瘤病死率首位。其病因不明,但多个卵巢癌高危因素已被研究发现证实。其中遗传性因素是最主要、最肯定的高危因素。对于BRCA1、2基因突变的高危人群,目前认为预防性双侧附件切除术是最有效的卵巢癌预防措施。除此之外,妊娠、哺乳、口服避孕药、输卵管结扎、子宫切除术等均被认为是卵巢癌保护性因素;而激素替代治疗、滑石粉、吸烟、肥胖等为卵巢癌高危因素,应注意避免其发生。 Epithelial ovarian cancer ( EOC ) is the leading cause of gynecological cancer deaths. Although the etiology of ovarian cancer is unclear, many associated risk factors have been identified. Chief among these is the family history of the disease. Hereditary ovarian cancer is responsible for about 5% - 10% of ovarian cancer cases. Based on the identification of these risk factors, the incidence of ovarian cancer can be reduced by pregnancy, lactation, the oral contraceptive pill and tubal ligation. Some evidence suggests the risk can also be reduced by eating a diet rich in fruit and vegetables, avoiding smoking, avoiding, being overweight and avoiding long-term use of unopposed hormonal replacement therapy (HRT). Strategies available to high-risk women include screening and prophylactic salpingooophoreetomy, which is the most effective method ofcancer risk reduction in women with a BRCA1,2 gene mutation. Besides, more and more evidence shows that oral contraceptives are also protective to ovarian cancer.
作者 孔北华 宋坤
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2010年第9期660-663,共4页 Chinese Journal of Practical Gynecology and Obstetrics
关键词 卵巢肿瘤 基因突变 激素替代治疗 ovarian cancer genic mutation hormonal replacement terapy
  • 相关文献

参考文献26

  • 1Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: result from a Swedish case-control study[J]. Am J Epidemiol, 2002,156:363-373. 被引量:1
  • 2Danforth KN, Tworoger SS, Hecht JL, et al. Breastfeeding and risk of ovarian cancer in two prospective cohorts [ J ]. Cancer Causes Control, 2007, 18:517-523. 被引量:1
  • 3Titus-Ernstoff L, Perez K, Cramer DW, et al. Menstrual and reproductive factors in relation to ovarian cancer risk [ J ]. British Journal of Cancer, 2001,84: 714-721. 被引量:1
  • 4Brinton LA, Lamb E J, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs [ J ]. Obstetrics and Gynecology, 2004,103 : 1194-1203. 被引量:1
  • 5Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: The Women 's Health Initiative Randomized Trial [J]. J Am Med Assoc, 2003, 290:1739-1748. 被引量:1
  • 6Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer[ J]. J Am Med Assoe, 2002, 288:334-341. 被引量:1
  • 7Lacey JV, Brinton LA, Leitzmann MF, et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Heahh-AARP Diet and Health Study Cohort [ J]. J Natl Cancer Inst, 2006,98 (19) : 1397-405. 被引量:1
  • 8Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women[ J]. J Natl Cancer Inst, 2002,94:497-505. 被引量:1
  • 9Beral V. Million Women Study Collaborators:ovarian cancer and hormone replacement therapy in the Million Women Study [ J ]. Lancet, 2007, 369(9574) : 1703-1710. 被引量:1
  • 10Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy and risk of ovarian cancer, a prospective study [J]. J Am Med Assoc, 1993, 270:2813-2818. 被引量:1

同被引文献111

引证文献9

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部